GPR119 is expressed predominantly in the pancreas and gastrointestinal tract in rodents and humans, as well as in the brain in rodents.[9] Activation of the receptor has been shown to cause a reduction in food intake and body weight gain in rats.[9] GPR119 has also been shown to regulate incretin and insulinhormone secretion.[10][11][12] As a result, new drugs acting on the receptor have been suggested as novel treatments for obesity and diabetes.[9][11][13]
^Izzo AA, Sharkey KA (Apr 2010). "Cannabinoids and the gut: new developments and emerging concepts". Pharmacology & Therapeutics. 126 (1): 21–38. doi:10.1016/j.pharmthera.2009.12.005. PMID20117132.
^Shah U (Jul 2009). "GPR119 agonists: a promising new approach for the treatment of type 2 diabetes and related metabolic disorders". Current Opinion in Drug Discovery & Development. 12 (4): 519–32. PMID19562648.
^Semple G, Fioravanti B, Pereira G, Calderon I, Uy J, Choi K, Xiong Y, Ren A, Morgan M, Dave V, Thomsen W, Unett DJ, Xing C, Bossie S, Carroll C, Chu ZL, Grottick AJ, Hauser EK, Leonard J, Jones RM (Sep 2008). "Discovery of the first potent and orally efficacious agonist of the orphan G-protein coupled receptor 119". Journal of Medicinal Chemistry. 51 (17): 5172–5. doi:10.1021/jm8006867. PMID18698756.
^Jones RM, Leonard JN, Buzard DJ, Lehmann J (Oct 2009). "GPR119 agonists for the treatment of type 2 diabetes". Expert Opinion on Therapeutic Patents. 19 (10): 1339–59. doi:10.1517/13543770903153878. PMID19780700. S2CID33083682.
